Advertisement
Canada markets closed
  • S&P/TSX

    22,167.03
    +59.95 (+0.27%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CAD/USD

    0.7384
    -0.0002 (-0.03%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • Bitcoin CAD

    95,044.53
    -380.20 (-0.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • RUSSELL 2000

    2,124.55
    +10.20 (+0.48%)
     
  • 10-Yr Bond

    4.2060
    +0.0100 (+0.24%)
     
  • NASDAQ

    16,379.46
    -20.06 (-0.12%)
     
  • VOLATILITY

    13.01
    0.00 (0.00%)
     
  • FTSE

    7,952.62
    +20.64 (+0.26%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • CAD/EUR

    0.6837
    -0.0006 (-0.09%)
     

RDInvesting Provides Investors with Free In-Depth Equity Reports on AZN, DD, GSK and NVS

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

AstraZeneca plc (NYSE:AZN - News) shares increased 1.45 percent to close at $59.37 a share Thursday. The stock traded between $58.69 and $59.42 on volume of 1.75 million shares traded. Analysts at UBS have recently initiated coverage on the company with a "buy" rating. Shares of AstraZeneca have fallen approximately 23.0 percent in the past year.

Find out more about AstraZeneca including full access to the free equity report at:
www.RDInvesting.com/AZN

E I Du Pont De Nemours And Co. (NYSE:DD - News) shares increased 1.28 percent to close at $63.94 a share Thursday. The stock traded between $63.25 and $64.24 on volume of 6.63 million shares traded. Analysts at Bank of America Merrill Lynch have recently upgraded the company’s rating to "buy" from "neutral". Shares of Du Pont have gained approximately 40.0 percent in the past year.

ADVERTISEMENT

Find out more about Du Pont including full access to the free equity report at:
www.RDInvesting.com/DD

GlaxoSmithKline plc (NYSE:GSK - News) shares gained 0.21 percent to close at $52.84 a share Thursday. The stock traded between $52.60 and $53.29 on volume of 2.45 million shares traded. Analysts at UBS have recently initiated coverage on the company with a "neutral" rating. Shares of GlaxoSmithKline have gained approximately 20.0 percent in the past year.

Find out more about GlaxoSmithKline including full access to the free equity report at:
www.RDInvesting.com/GSK

Novartis AG (NYSE:NVS - News) shares increased 1.38 percent to close at $80.81 a share Thursday. The stock traded between $79.27 and $81.04 on volume of 2.70 million shares traded. Analysts at UBS have recently initiated coverage on the company with a "buy" rating. Shares of Novartis have gained approximately 25.0 percent in the past year.

Find out more about Novartis including full access to the free equity report at:
www.RDInvesting.com/NVS

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:
Research Driven Investing
info@rdinvesting.com